ALLMedicine™ Inferior Vena Cava Filters Center

Jul 31st, 2021 - Venous thromboembolism (VTE) affects approximately 17,000 Australians annually. While anticoagulation is the mainstay of treatment, inferior vena cava filters (IVCFs) are used in patients where this is contraindicated. The primary aim was to ident...

Jul 20th, 2021 - A 77 year old woman with recent history of vertebroplasty for treatment of multiple osteoporotic lumbar vertebral body compression fractures presented for post-procedure care. A series of radiographs and cross-sectional imaging of the lumbar spine...

Jun 28th, 2021 - A lack of high-quality research and data has restricted the comprehensive understanding of the conversion procedure of convertible inferior vena cava filters. The aim of this study was to present an unusual situation with a high risk of causing co...

Jun 19th, 2021 - Introduction: Inferior vena cava (IVC) filters are mechanical filtration devices designed as an alternative to surgical ligation/plication of the IVC. Their use has been controversial, especially with the introduction of retrievable filters and ex...

May 15th, 2021 - Retrievable inferior vena cava filters (IVCF) have been increasingly used for mechanical pulmonary embolism prophylaxis since their development. The Captus Vascular Retrieval System (Avantec Vascular, Sunnyvale, California) is a new device develop...

Sep 14th, 2020 - To provide evidence-based recommendations on the use of inferior vena cava (IVC) filters in the treatment of patients with or at substantial risk of venous thromboembolic disease. A multidisciplinary expert panel developed key questions to address...

May 6th, 2019 - Venous thromboembolism (VTE)-deep vein thrombosis and pulmonary embolism-is a common cause of morbidity and mortality. The mainstay of VTE prophylaxis and therapy is anticoagulation. In select patients with VTE, inferior vena cava (IVC) filters ar...

Mar 9th, 2018 - The risk of venous thromboembolism (VTE) is very high in trauma patients, secondary to tissue injury, venous status from immobilization, and thrombophilia. As such, early initiation of VTE prophylaxis is essential in this population. The competing...

Feb 26th, 2018 - PRESERVE is a multi-center, prospective, open-label, non-randomized investigation of commercially available IVC filters from 6 manufacturers placed in subjects for the prevention of pulmonary embolism (PE). This study will enroll approximately 1,8...

Jun 8th, 2016 - The development of clots is a potentially deadly complication in many cancer patients. The current optimal treatment is unknown. Evidence supporting the effectiveness of the use of Inferior Vena Caval Filters is lacking. This study will compare th...

Jun 21st, 2013 - The registry is a multi-institutional bioinformatics database for the collection of data relevant to Inferior vena cava filters. Participating study centers may enroll patients and enter data in the web-based registry that include demographics, cl...

Nov 18th, 2020 - The guidelines on the use of inferior vena cava (IVC) filters in the treatment of patients with venous thromboembolism (VTE; ie, deep vein thrombosis [DVT] or pulmonary embolism [PE]) were published in October 2020 by the Society of Interventional...

Nov 18th, 2020 - The guidelines on the use of inferior vena cava (IVC) filters in the treatment of patients with venous thromboembolism (VTE; ie, deep vein thrombosis [DVT] or pulmonary embolism [PE]) were published in October 2020 by the Society of Interventional...

Jun 17th, 2019 - Use of prophylactic inferior vena cava filters (IVCFs) was tied to worse outcomes after bariatric surgery, a retrospective study indicated. Among 1,047 patients who received prophylactic IVCFs prior to bariatric surgery, in-hospital mortality or p...

Jul 7th, 2016 - The Absorb bioresorbable vascular scaffold was green-lighted by the FDA for the treatment of coronary artery disease. The fully dissolving stent disappears within 3 years. Chocolate that goes straight to your heart? Europe gave the CE Mark to the ...

Dec 21st, 2015 - A pill, dubbed KIT-302, that combines celecoxib and amlodipine not only treated osteoarthritis pain without increasing blood pressure but also reduced blood pressure better than amlodipine alone in a phase III trial. Trends-in-Medicine's Lynne Pet...